During September 2022, the CIDG published one new protocol, one new review, and two review updates in Issue 9, 2022 of the Cochrane Database of Systematic Reviews.
Pérez-Gaxiola G, Velásquez-Salazar P, Veroniki AA, Zambrano-Rico S, Hernández Alcaraz M, Cuello-García CA, Florez ID. Interventions for treating head lice: a network meta‐analysis.
Reis S, Metzendorf M-I, Kuehn R, Popp M, Gagyor I, Kranke P, Meybohm P, Skoetz N, Weibel S. Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19.
- Kay AW, Ness T, Verkuijl SE, Viney K, Brands A, Masini T, González Fernández L, Eisenhut M, Detjen AK, Mandalakas AM, Steingart KR, Takwoingi Y. Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.
- Allen EN, Wiyeh AB, McCaul M. Adding rapid diagnostic tests to community‐based programmes for treating malaria.
Updated podcast “How accurate are rapid antigen tests for diagnosing COVID-19?”
Throughout 2022, we will continue to add publications to our CIDG and READ-It websites regularly. Do continue to check our websites for updates and follow us on Twitter.
The CIDG editorial base is located at the Liverpool School of Tropical Medicine in Liverpool, UK. Over 600 authors from some 52 countries contribute to the preparation of the Cochrane Reviews. They are supported by an international team of Editors, each with topic or methodological expertise. The CIDG’s main areas of work are on determination of the effects of interventions on the prevention or treatment infectious diseases of relevance to the United Nations Sustainable Development Goals.